BofA raised the firm’s price target on Teladoc (TDOC) to $8.75 from $7 and keeps a Neutral rating on the shares. Teladoc’s recent acquisitions of Catapult and Uplift provide optionality to drive higher revenue per member, but it will take both time and execution to improve the revenue growth outlook, the analyst tells investors in a research note. BofA remains cautious on full-year guidance and momentum into 2026 but views recent acquisitions as potential catalysts for growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Teladoc’s Growth Challenges and Long-Term Potential: Analyst Maintains Hold Rating
- Omada Health initiated with an Overweight at Barclays
- Unusually active option classes on open June 25th
- Unusually active option classes on open June 24th
- Morning Movers: TD Synnex slips following second quarter results